NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer
Autor: | Gregor Cammerer, Jochen Pressmar, Kerstin Stecker, Hans G. Beger, Bernd M. Muehling, Frank Gansauge, Susanne Gansauge, Gerd Leder, Marco Ramadani |
---|---|
Rok vydání: | 2002 |
Předmět: |
Adult
Male Antimetabolites Antineoplastic medicine.medical_specialty Berberine Alkaloids Antineoplastic Agents Adenocarcinoma Deoxycytidine Gastroenterology law.invention Alkaloids Randomized controlled trial law Internal medicine Pancreatic cancer Antineoplastic Combined Chemotherapy Protocols medicine Humans Prospective Studies Prospective cohort study Survival analysis Aged Aged 80 and over business.industry Middle Aged medicine.disease Survival Analysis Gemcitabine Phenanthridines Surgery Pancreatic Neoplasms Treatment Outcome Cardiothoracic surgery Injections Intravenous Toxicity Drug Therapy Combination Female business Abdominal surgery medicine.drug |
Zdroj: | Langenbeck’s Archives of Surgery. 386:570-574 |
ISSN: | 1435-2451 1435-2443 |
DOI: | 10.1007/s00423-001-0267-5 |
Popis: | Background: NSC-631570 (Ukrain) is a semisynthetic compound of thiophosphoric acid and the alkaloid chelidonine from the plant Chelidonium majus. It has been used in complementary herbal medicine for more than 20 years for the treatment of benign and malignant tumors. Patients/methods: Between August 1999 and June 2001, 90 patients with histologically proven unresectable pancreatic cancer were randomized in a monocentric, controlled, randomized study. Patients in arm A received 1000 mg gemcitabine/m2, those in arm B received 20 mg NSC-631570, and those in arm C received 1000 mg gemcitabine/m2 followed by 20 mg NSC-631570 weekly. End point of the study was overall survival. Results: In all three arms therapy was well tolerated and toxicity was moderate. At the first re-evaluation in arm A 32%, in arm B 75%, and in arm C 82% showed no change or partial remission according to WHO criteria (arm A versus arm B: P |
Databáze: | OpenAIRE |
Externí odkaz: |